Anupam Rasayan India Limited

PE of 78.77 paired with ROE of 5.5% suggests market priced in earnings growth not yet realized; verify catalysts and earnings trajectory to justify current valuation

ROE of 5.5% indicates poor capital efficiency — returns far below cost of equity; assess whether this is temporary or structural to the business

Operating margins swung from 18.57% to 33.28% within 12 months; clarify drivers of volatility and sustainability at different levels

1-year return of 7.28% lags the valuation multiple; assess whether market has repriced expectations or current earnings miss prior guidance

Operating margin peak of 33.28% (Jun 2026) vs. current 22.2% average — margin expansion even at flat revenue would double profitability; identify product mix, pricing and cost drivers

Consolidated revenue scale of ₹600–730 Cr shows trajectory with operational benefits from higher fixed-cost absorption; verify capex cycle and capacity utilization

Six dividend payments since 2023 demonstrate cash generation; clarify if this reflects strong FCF conversion or suboptimal capital structure informing capex funding

Specialty chemicals positioning typically supports pricing power and customer switching costs vs. commodities; verify end-market exposure (pharma, agro, FMCG) and contract terms